

# Obstructive Sleep Apnoea and Polycystic Ovary Syndrome; a comprehensive review of clinical interactions and underlying pathophysiology

Kahal, Hassan; Kyrou, Ioannis; Tahrani, Abd A; Randeva, Harpal S

DOI:

[10.1111/cen.13392](https://doi.org/10.1111/cen.13392)

License:

None: All rights reserved

Document Version

Peer reviewed version

Citation for published version (Harvard):

Kahal, H, Kyrou, I, Tahrani, AA & Randeva, HS 2017, 'Obstructive Sleep Apnoea and Polycystic Ovary Syndrome; a comprehensive review of clinical interactions and underlying pathophysiology', *Clinical Endocrinology*. <https://doi.org/10.1111/cen.13392>

[Link to publication on Research at Birmingham portal](#)

## Publisher Rights Statement:

Eligibility for repository: Checked on 11/7/2017

## General rights

Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes permitted by law.

- Users may freely distribute the URL that is used to identify this publication.
- Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private study or non-commercial research.
- User may use extracts from the document in line with the concept of 'fair dealing' under the Copyright, Designs and Patents Act 1988 (?)
- Users may not further distribute the material nor use it for the purposes of commercial gain.

Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.

When citing, please reference the published version.

## Take down policy

While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been uploaded in error or has been deemed to be commercially or otherwise sensitive.

If you believe that this is the case for this document, please contact [UBIRA@lists.bham.ac.uk](mailto:UBIRA@lists.bham.ac.uk) providing details and we will remove access to the work immediately and investigate.

CLINICAL  
ENDOCRINOLOGY

**Obstructive Sleep Apnoea and Polycystic Ovary Syndrome; a comprehensive review of clinical interactions and underlying pathophysiology.**

Journal:	<i>Clinical Endocrinology</i>
Manuscript ID:	CEN-2017-000282.R1
Manuscript Type:	5 Unsolicited Review
Date Submitted by the Author:	n/a
Complete List of Authors:	Kahal, Hassan; University of Warwick Warwick Medical School, Division of Translational and Experimental Medicine; University Hospitals Coventry and Warwickshire NHS Trust, Warwickshire Institute for the Study of Diabetes, Endocrinology and Metabolism (WISDEM) Kyrou, Ioannis ; University of Warwick Warwick Medical School, Division of Translational and Experimental Medicine; University Hospitals Coventry and Warwickshire NHS Trust, Warwickshire Institute for the Study of Diabetes, Endocrinology and Metabolism (WISDEM); Aston University, Aston Medical Research Institute, Aston Medical School, Tahrani, Abd; University of Birmingham, Institute of Metabolism and Systems Research, School of Clinical and Experimental Medicine; University of Birmingham, Centre of Endocrinology, Diabetes and Metabolism (CEDAM); Birmingham Heartlands Hospital, Department of Diabetes Randeve, Harpal; University of Warwick Warwick Medical School, Division of Translational and Experimental Medicine; University Hospitals Coventry and Warwickshire NHS Trust, Warwickshire Institute for the Study of Diabetes, Endocrinology and Metabolism (WISDEM); Aston University, Aston Medical Research Institute, Aston Medical School,
Key Words:	Polycystic ovary syndrome < Conditions: < Ovary, Obstructive sleep apnoea, Obesity, morbid < Conditions: < Obesity/Lipids/Nutrition, Hyperandrogenism, Insulin resistance < Conditions: < Pancreas

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Title: Obstructive Sleep Apnoea and Polycystic Ovary Syndrome; a comprehensive review of clinical interactions and underlying pathophysiology.**

Hassan Kahal<sup>1,2</sup>, Ioannis Kyrou<sup>1,2,3</sup>, Abd A Tahrani<sup>4,5,6</sup>, Harpal S. Randeva<sup>1,2,3</sup>

<sup>1</sup>Division of Translational and Experimental Medicine, Warwick Medical School, University of Warwick, Coventry CV4 7AL, United Kingdom.

<sup>2</sup>Warwickshire Institute for the Study of Diabetes, Endocrinology and Metabolism (WISDEM), University Hospitals Coventry and Warwickshire NHS Trust, Coventry CV2 2DX, United Kingdom.

<sup>3</sup>Aston Medical Research Institute, Aston Medical School, Aston University, Birmingham, B4 7ET, United Kingdom.

<sup>4</sup>Institute of Metabolism and Systems Research, School of Clinical and Experimental Medicine, University of Birmingham, Birmingham, B15 2TT, United Kingdom.

<sup>5</sup>Centre of Endocrinology, Diabetes and Metabolism (CEDAM), Birmingham Health Partners, Birmingham, UK

<sup>6</sup>Department of Diabetes, Birmingham Heartlands Hospital, Birmingham, UK

**Short title:** PCOS and OSA links

**Key words:** Polycystic ovary syndrome; PCOS; Obstructive Sleep Apnoea; OSA; Hyperandrogenism; Obesity; Insulin Resistance.

Manuscript: 3214 words (excluding abstract, tables, and figures). Number of Tables: 1. Number of Figures: 1. Abstract: 153 words. References: 58.

**Corresponding Author:** Professor Harpal Randeva. Warwickshire Institute for the Study of Diabetes, Endocrinology and Metabolism (WISDEM), University Hospitals Coventry and Warwickshire NHS Trust, Coventry CV2 2DX, Email: [Harpal.Randeva@warwick.ac.uk](mailto:Harpal.Randeva@warwick.ac.uk)

**Declaration of interest:** The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the paper reported. No funding was received for doing this work. Dr Abd Tahrani is a Clinician Scientist supported by the National Institute for Health Research. The views expressed in this publication are those of the author(s) and not necessarily those of the NHS, the National Institute for Health Research or the Department of Health. NIHR Clinical Lectureship supported Dr. Hassan Kahal. All authors reviewed and edited the manuscript and approved the final version of the manuscript.

34     **Abstract**

35     Polycystic ovary syndrome (PCOS) is the most prevalent endocrine disorder in women of  
36     reproductive age. PCOS is associated with multiple co-morbidities including, obesity, insulin  
37     resistance and type 2 diabetes, as well as mood disorders and impaired quality of life (QoL).  
38     Obstructive sleep apnoea (OSA) is also a common medical condition that is often  
39     undiagnosed, particularly in women. OSA is associated with a similar spectrum of  
40     comorbidities to that observed in PCOS, including manifestations of the metabolic syndrome  
41     and impaired QoL, whilst obesity frequently constitutes a common denominator in the  
42     pathophysiology of both OSA and PCOS. Hence, it is not surprising that OSA and PCOS  
43     may co-exist in women of reproductive age, and the current clinical guidelines on the  
44     management of PCOS recommend screening for OSA symptoms in overweight/obese women  
45     with PCOS. In this review, we examine the relationship between OSA and PCOS and explore  
46     the potential underlying mechanisms that link these two conditions.

47

## 1. Introduction

Polycystic ovary syndrome (PCOS) is the most common **endocrine** disorder in women of reproductive age with a prevalence of 6–15% (3, 4). PCOS is associated with obesity, subfertility, insulin resistance (IR) and type 2 diabetes (T2DM), depression and impaired quality of life (QoL) (1, 5). **However, despite its high prevalence and significant comorbidities, our understanding of its underlying pathophysiology remains poor; with limited treatment options available to manage this lifelong disorder in everyday clinical practice.**

Hence, there is a need to improve the understanding of the pathogenesis of PCOS and the spectrum of factors that might contribute to the clinical manifestations and comorbidities of this very common condition.

Obstructive sleep apnoea (OSA) is also an obesity-related disorder. OSA prevalence in the general population is estimated at 17–26% in men and 9–28% in women, but this difference varies depending on the definition and methods used to diagnose OSA (6). OSA is characterised by recurrent episodes of partial (hypopnoea) or complete (apnoea) upper airway obstructions associated with recurrent oxygen desaturations and cyclical changes in heart rate, blood pressure, intrathoracic pressure and sympathetic activity (7). In addition, OSA results in changes in the sleep architecture, including loss of deep sleep (stages 3 and 4) and/or of REM sleep (7).

Patients with OSA may present with nocturnal symptoms, including snoring, witnessed apnoea episodes, choking or gasping, insomnia, nocturia, enuresis, frequent arousals, diaphoresis, and impotence (8). In addition, common daytime OSA symptoms may include excessive daytime sleepiness, fatigue, memory impairment, morning headaches, and depression (8). Prompt diagnosis and treatment of OSA is highly important in clinical practice, since undiagnosed/untreated OSA is associated with increased risk of hypertension,

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

72 cardiovascular disease, mortality, IR and T2DM, road traffic accidents, depression and  
73 impaired QoL (8, 9) . Continuous positive airway pressure (CPAP) therapy, combined with  
74 weight loss for overweight/obese patients, is the treatment of choice for symptomatic OSA  
75 (10).

76 Despite the high prevalence of OSA in the general population, this condition is generally  
77 under-recognised and frequently remains undiagnosed in everyday clinical practice,  
78 particularly in women who may not present with typical OSA symptoms (11). As obesity is a  
79 common risk factor, it is not surprising that OSA and PCOS might co-exist. The association  
80 between PCOS and OSA has also been recognised in the latest guidelines by the European  
81 and the US Endocrine Societies (Box 1) (1, 2). However, these guidelines acknowledge the  
82 limited evidence behind their recommendations that is largely based on limited, ‘weak’, or  
83 ‘low quality’ data. This highlights the need for further research to better understand the  
84 relationship between PCOS and OSA. In addition, the implications of OSA in women with  
85 PCOS are not clear, though important as both conditions are associated with overlapping  
86 comorbidities, and OSA is associated with essential factors that may contribute to the burden  
87 of PCOS (e.g. to IR, increased inflammation, and oxidative stress) (6, 12). In this article we  
88 present a concise review of key studies that examined the relationship between OSA and  
89 PCOS, and we explore the potential mechanisms linking both conditions.

**Box 1. Clinical guidelines/recommendations on screening women with PCOS for OSA.**

1. Endocrine Society, 2013 (1):  
We suggest screening overweight/obese adolescents and women with PCOS for symptoms suggestive of OSA and, when identified, obtaining a definitive diagnosis using polysomnography. If OSA is diagnosed, patients should be referred for institution of appropriate treatment.
2. European Society of Endocrinology, 2014 (2):  
It seems wise at this moment to screen sleep disorders by clinical questionnaires in obese women with PCOS. In the case of clinical suspicion resulting from these questionnaires, patients should be referred to a centre of sleep disorders for polysomnography and further evaluation.

## 2. Methodology

We conducted a narrative review of the relevant literature. In this context, we searched PubMed using the terms ‘(PCOS OR polycystic ovary syndrome) AND (OSA OR obstructive sleep apnoea OR obstructive sleep apnea)’. Clinical studies and review articles examining the presence of OSA in women with PCOS were obtained, reviewed, and their results were critically appraised. We also hand-searched references from relevant papers and review articles.

## 3. Epidemiology

### 3.1 PCOS prevalence in OSA

PCOS has a prevalence of 6–15% in women of reproductive age (3); however, the reported prevalence rates vary depending on the populations studied and the applied PCOS diagnostic criteria. The prevalence of PCOS in women with OSA remains unknown.

103

### 3.2 OSA prevalence in PCOS

The prevalence of OSA in the general population varies considerably between studies, mainly due to differences in the populations studied, study designs, and the methods and criteria used to diagnose OSA (8). The prevalence from three well-conducted studies with similar designs from the USA (Wisconsin and Pennsylvania), and Spain showed an OSA prevalence of 9–28% in women, with 2–7% for moderate to severe OSA (13).

To date, a limited number of studies have examined the prevalence of OSA in women with PCOS with the majority of these being conducted in the USA. Based on the existing published studies (14-22) (Table 1), the reported prevalence of OSA in women with PCOS



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

113 ranges from 0% to 69% (median: 55.8%; mean: 39.8%). This large variability and wide range  
114 in the reported prevalence may be attributed to a combination of reasons, including  
115 application of different cut-off points and methods to diagnose OSA, the small size of the  
116 studied cohorts, and potential selection bias by recruitment of study participants from  
117 specialised clinics. As expected, the available data suggest that OSA risk in women with  
118 PCOS is increased with age and obesity. While the only published study that examined the  
119 presence OSA in lean women with PCOS showed no evidence of the condition (18), the  
120 small number of study participants (n=18) precludes generalisability or drawing firm  
121 conclusions from these data. The reported prevalence and potential links between PCOS and  
122 OSA in adolescents are even more controversial, with one study showing a prevalence of  
123 16/28 (57%) (20) and another showing 0/22 (0%) prevalence (19). Based on the available  
124 data on the prevalence and natural history of these two conditions, it is probable that PCOS  
125 precedes the development of OSA; however, it cannot be excluded that OSA may precede the  
126 clinical presentation of PCOS in some women, worsening the PCOS-related  
127 symptomatology. Observational long-term studies are needed to accurately assess the  
128 incidence of OSA in women with PCOS and *vice versa*.

129  
130 **4. Proposed mechanisms linking OSA to PCOS and its comorbidities**

131 Depending on ethnicity and geography, 30–88% of women with PCOS are overweight or  
132 obese (23). Obesity may contribute to the development of PCOS through increased android  
133 (central) type adiposity and IR (24); lipotoxicity (25); and increased 5 $\alpha$ -reductase activity  
134 (23). Obesity is also a major risk factor for OSA (8). The mechanisms that link obesity to  
135 OSA are multifactorial (8, 26). Weight gain can alter normal upper airway mechanics during  
136 sleep by various mechanisms, such as increased parapharyngeal fat deposition resulting in a

smaller upper airway; altering the neural compensatory mechanisms that maintain airway patency; reducing the functional residual capacity with a resultant decrease in the stabilising caudal traction on the upper airway; reducing lung volume due to increased abdominal fat; increasing breathing workload due to increased chest wall thickness; and affecting the chemosensitivity to O<sub>2</sub> and CO<sub>2</sub> which reduces the ventilatory drive (8, 26). Subsequently, obesity is a key factor that predisposes to both PCOS and OSA. However, other shared features between PCOS and OSA may also play an important mechanistic role in the development/interaction between these two common conditions.

#### 4.1 Sex Hormones

An increase in circulating androgens of ovarian origin is one of the main features of PCOS and is present in both ovulatory and anovulatory women. Androgens cause many of the clinical features of PCOS (*e.g.* hirsutism, acne and alopecia); contribute to anovulation by promoting ovarian early follicular growth and subsequently disrupt follicular development and dominant follicle selection (27); and exacerbate IR. Anovulation will result in lower progesterone levels. Hyperandrogenism and low progesterone levels may play a role in the pathogenesis of OSA by increasing upper airway collapsibility, and/or impairing the sensitivity and responsiveness of the ventilatory chemoreceptors (28). However, the effect of hyperandrogenism on OSA risk in women with PCOS is probably small, as androgen levels are relatively low compared to men. Sleep, on the other hand, appears to have a significant effect on the female hormone production (29). Indeed, sleep deprivation and/or interruption, and sleep disordered breathing have been suggested to influence gonadotropin releasing hormone (GnRH), follicular stimulating hormone (FSH) and luteinising hormone (LH) pulsatility and may cause menstrual disturbances (30, 31). Subsequently, OSA may alter sex hormones production and contribute to the development or worsening of the clinical features of PCOS.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

162     **4.2 Insulin resistance**

163     IR is seen in more than 50% of women with PCOS, independent of obesity (32). Insulin may  
164     act directly on the ovaries to enhance androgen production (33); reduce SHBG production  
165     from the liver with subsequent increase in bioavailable testosterone; and cause the premature  
166     arrest of follicle growth and anovulation (34). Most studies also suggest an association  
167     between OSA and IR (8); and studies in healthy lean men found OSA to be associated with  
168     IR even in the absence of obesity (35). In addition, in a cohort study, OSA, apnoea/hypopnea  
169     index (AHI), oxygen desaturation index (ODI), and minimal oxygen saturations were  
170     independently associated with IR development over an 11-year follow-up period after  
171     adjustment for age, baseline BMI, BMI change over follow-up, hypertension, and CPAP  
172     treatment (36). Two recent meta-analyses showed that CPAP treatment was associated with a  
173     reduction in the homeostasis model assessment of insulin resistance (HOMA-IR) (37, 38),  
174     although this benefit may occur only in those using CPAP >4 hours per night (39).  
175     Subsequently, it is plausible that OSA, through IR, may contribute to the development of a  
176     more severe PCOS phenotype in women affected by both conditions; or to a *de novo*  
177     presentation of PCOS in genetically/metabolically predisposed women.

178     **4.3 Oxidative stress**

179     In a recent systematic review and meta-analysis, PCOS was associated with increased levels  
180     of oxidative stress, independent of age and BMI (40). Oxidative stress may play a role in the  
181     pathogenesis of PCOS by exacerbating IR (41); causing hyperandrogenism (41); and  
182     contributing to infertility (42). Many studies suggest that OSA is a cause of oxidative stress  
183     (8). Recurrent hypoxia and mitochondrial dysfunction in OSA result in the formation of  
184     reactive oxygen species (ROS) which leads to cellular and DNA damage and oxidative stress

(43). Subsequently, OSA may complicate the clinical picture in PCOS by promoting oxidative stress.

#### 4.4 Endothelial dysfunction

Women with PCOS have been found to have lower flow-mediated dilatation (FMD) compared to age- and weight-matched controls (44). Obesity, IR, oxidative stress, advanced glycation end products (AGE) and inflammation are believed to play a role in the pathogenesis of endothelial dysfunction in PCOS (45). OSA is also associated with endothelial dysfunction and the underlying mechanisms are likely related to ischemia-reperfusion injury (46). Repetitive episodes of re-oxygenation after hypoxemia in patients with OSA result in increased production of AGE and ROS (43); altered protein kinase C signaling; decreased endothelial nitric oxide synthase (47); increased endothelin-1 levels and inflammation (48). Notably, CPAP treatment was found to increase FMD in patients with OSA (49).

#### 4.5 Sympathetic activity

Sympathetic activity is increased in obesity and is associated with visceral adiposity (50); high leptin levels (51) and IR (52) are thought to play a role in its pathogenesis. However, increased sympathetic activity may further exacerbate IR and creates a vicious cycle (52). Women with PCOS have evidence of increased sympathetic activity (52), even in the absence of obesity (53). Sympathetic activity may contribute to the pathogenesis of PCOS through increased IR, altered ovarian function and the development PCO morphology (52). OSA is also associated with an increase in sympathetic activity independent of body weight (54). It is likely that both the recurrent hypoxia (55) and recurrent arousals (56) contribute to the activation of the sympathetic nervous system (SNS). Moreover, treatment with CPAP is associated with a reduction in sympathetic activity (57).

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

209 **4.6 Summary of the proposed mechanisms linking OSA and PCOS**

210 OSA and PCOS are both associated with comorbidities including obesity, IR, oxidative  
211 stress, endothelial dysfunction, sympathetic hyperactivity, and hormonal disturbances that  
212 could potentially contribute to the pathophysiology and development of either condition. It is  
213 thus plausible that the relationship between OSA and PCOS is bidirectional, where PCOS  
214 contributes to the development of OSA, and *vice versa*, OSA contributes to the clinical  
215 presentation of PCOS, worsening its symptomatology and creating a vicious cycle between  
216 the two conditions. An illustration of the possible pathophysiological links between OSA and  
217 PCOS and their clinical consequences is provided in Figure 1.

220 **5. The impact of OSA in women with PCOS**

221 **5.1 Review of published studies**

222 A limited number of studies have examined the effect(s) of OSA in women with PCOS and  
223 their findings are summarised in Table 1.

224 In the study by Vgontzas *et al.* (15), women with PCOS and sleep disordered breathing (SDB  
225 was defined as either OSA or upper airway resistance syndrome; n=9) were heavier (BMI  
226  $45.7 \pm 2.6$  vs.  $37.2 \pm 1.1$  kg/m<sup>2</sup>, P<0.003), and had higher fasting insulin ( $306.5 \pm 52.4$  vs.  
227  $176.1 \pm 18.5$  pmol/L, P<0.01) and lower glucose-to-insulin ratio ( $0.02 \pm 0.006$  vs.  $0.04 \pm 0.003$ ,  
228 P<0.05) compared to women with PCOS without SDB (n=44). Logistic regression analysis of  
229 the study data showed that insulin levels and glucose-to-insulin ratio had a stronger  
230 association with SDB than age, BMI, or testosterone levels. However, the difference in BMI  
231 between the two groups in this study was rather high (8.5 kg/m<sup>2</sup>), and despite statistical

adjustment, it is difficult to completely rule out an effect of obesity on the metabolic differences between the two groups.

Similarly, in the study by Tasali *et al.* (17), women with PCOS and OSA (n=29) were older (age  $31.6 \pm 1.0$  vs.  $27.3 \pm 0.7$  years;  $P=0.002$ ), had a higher BMI ( $42.2 \pm 1.1$  vs.  $35.3 \pm 1.4$  kg/m<sup>2</sup>;  $P<0.001$ ), and were more insulin resistant (HOMA-IR  $5.7 \pm 0.4$  vs.  $3.5 \pm 0.4$ ,  $P=0.006$ ) than women with PCOS without OSA (n=23). After controlling for age, BMI, and ethnicity, AHI was a highly significant predictor of the fasting concentrations of glucose and insulin, as well as of the 2-h glucose concentration (after an oral glucose tolerance test) and HOMA-IR. The data of this study also suggest that the degree of sleep fragmentation, rather than the severity of hypoxia, may be related to the severity of IR and glucose intolerance in women with PCOS. As such, the authors further concluded that women with PCOS and OSA represent a metabolically different, 'higher risk' population compared to women with PCOS without OSA. However, this conclusion should be taken with caution considering the small study sample size, and the relatively large difference in BMI (7.1 kg/m<sup>2</sup>) between women with and without OSA in this study.

Notably, Tasali *et al.* have also conducted a relevant short-term interventional study (58) in 19 obese women with PCOS and OSA (age  $\pm$  SEM:  $31.2 \pm 1.2$  years; BMI:  $46.4 \pm 2.4$  kg/m<sup>2</sup>). These women were treated with CPAP for 8 weeks, exhibiting subsequent improvement in insulin sensitivity (relative increase of nearly 7%), and reduction in diastolic blood pressure (DBP; approximately 2.3 mmHg). In addition, day-time and night-time norepinephrine levels also reduced after CPAP therapy. However, this study lacked a control group, and only a 'per protocol' analysis was performed including just 9 study participants, with the data from another 10 study patients being excluded from the analysis due to lack of adequate CPAP treatment compliance (average use of CPAP <4 hours per night). Of note, whether the

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

reported post-treatment changes in IR and blood pressure observed in this study may translate/result into meaningful clinical outcomes remains to be studied.

In another study by Tock *et al.* (21), women with PCOS and OSA (n=12) had higher BMI (37.8±4.8 vs. 30.67±7.7 kg/m<sup>2</sup>, P=0.006); waist circumference (114.4±12.0 vs. 98.1±19.9 cm, P=0.013); waist-to-hip ratio (1.0±0.1 vs. 0.9±0.1, P=0.029); free testosterone (1.9±1.3 vs. 1.1±0.8 ng/dL, P=0.014); HOMA-IR (4.4±3.2 vs. 2.3±1.4, P=0.009); total cholesterol (205.0±28.7 vs. 172.3±35.8 mg/dL, P=0.009); low density lipoprotein-cholesterol (LDL, 128.6±21.6 vs. 98.9±29.6, P=0.004); and higher prevalence of non-alcoholic fatty liver disease (NAFLD, 83.3% vs. 26.9%, P<0.001) compared to those without OSA (n=26). After adjusting for obesity in multivariate logistic regression analysis, raised serum free testosterone levels ≥1.07 ng/dL increased the risk of OSA in women with PCOS by 8.2 fold. Accordingly, the authors concluded that hyperandrogenism may be a predisposing factor for OSA in PCOS. However, a limitation of this study is the fact that testosterone was measured by immunoassay rather than by tandem mass spectrometry. In a subsequent multiple logistic regression analysis, with OSA (AHI ≥5), IR (HOMA-IR ≥2.7), and obesity (BMI ≥30 kg/m<sup>2</sup>) considered as independent variables and NAFLD as the dependent variable, only OSA was an independent predictor of the presence of NAFLD. The presence of OSA increased the chance of NAFLD 7.6 fold in woman with PCOS. As such, the authors concluded that OSA is a predictor of NAFLD along with, but independent of, obesity and IR.

In a recent study by Chatterjee *et al.* (22), women with PCOS and SDB (n=33) had higher BMI (29.8±3.4 vs. 24.36±2.29 kg/m<sup>2</sup>, P<0.001), waist circumference (95.58±6.47 vs. 85.12±4.34, P<0.001), systolic BP (SBP, 129.27±10.93 vs. 119.18±8.03 mmHg, P=0.002), diastolic BP (78.61±9.07 vs. 73.53±6.22 mmHg, P=0.044), and hirsutism (Ferriman–Gallwey score 9.82±2.78 vs. 8.00±2.5, P=0.028) compared to women with PCOS without SDB



(n=17). Interestingly, in a logistic regression analysis which adjusted for BMI, only the associations between fasting plasma glucose and diastolic BP with SDB remained significant. Finally, in the study by Nandalike *et al.* (20), adolescent girls with PCOS and OSA (n=16) had higher prevalence of the metabolic syndrome (56.3% vs. 8.3%, P=0.03); higher HOMA-IR >4 (81.3% vs. 41.6%, P=0.03), systolic BP (128.4±12.8 vs. 115.6±11.4 mmHg, P=0.009), triglycerides (149.7±87.7 vs. 93.3±25.8 mg/dl, P=0.03), and lower high density lipoprotein (HDL, 38.6±8.7 vs. 49±10.9 mg/dl, P=0.01) compared to girls with PCOS without OSA (n=12).

## 5.2 Summary of the literature

It seems plausible that OSA is associated with the severity of the PCOS phenotype, particularly in overweight/obese and insulin resistant women with PCOS. However, it is difficult to draw firm conclusions from the studies conducted so far since significant variables (*e.g.* abdominal adiposity and ethnicity) have often not been accounted for in the presented analyses. In addition, while the association between OSA and increased insulin resistance in women with PCOS seems to be a common theme, the relationship between OSA and hyperandrogenism is more controversial and require further evaluation. While the US and European Endocrine societies' guidelines consider the presence of OSA as a cardiovascular risk factor in women with PCOS (1, 2), there is lack of data on the exact relationship between OSA and important clinical outcomes in women with PCOS (*e.g.* on T2DM risk, cardiovascular risk, subfertility, depression, and impaired QoL). Subsequently, well conducted observational studies are needed to examine the effects of OSA in women with PCOS. Interventional studies are also required in women with PCOS and OSA. The existing short-term, pilot, interventional study in such patients suggests that CPAP therapy



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

304 may significantly improve insulin sensitivity and reduce blood pressure. However, it remains  
305 unclear whether this can translate into long-term meaningful clinical outcomes.

306

307 **6. Conclusions**

308 OSA appears to be common in obese women with PCOS. There is a lack of high-quality  
309 evidence regarding the clinical benefit or the cost-effectiveness of the current Endocrine  
310 Society clinical practice guidelines which suggest screening all overweight/obese adolescents  
311 and women with PCOS for symptoms suggestive of OSA. While it is probable that PCOS  
312 precedes and contributes to the development of OSA, it is also plausible that OSA may  
313 contribute to the presentation and worsen the clinical manifestations of PCOS. Both  
314 conditions are associated with significant comorbidities in women (*e.g.* depression,  
315 unexplained fatigue, hypertension, dyslipidaemia, IR and impaired glucose tolerance), and  
316 may progress undiagnosed for prolonged periods. In order to inform clinical practice and  
317 support evidence-based guidelines, further clinical research is needed, including prospective  
318 cohort studies in obese and non-obese women with PCOS, to study in detail the relationship  
319 between these two important and prevalent conditions.

## References

1. Legro RS, Arslanian SA, Ehrmann DA, Hoeger KM, Murad MH, Pasquali R, et al. Diagnosis and treatment of polycystic ovary syndrome: an Endocrine Society clinical practice guideline. *J Clin Endocrinol Metab.* 2013;98(12):4565-92.
2. Conway G, Dewailly D, Diamanti-Kandarakis E, Escobar-Morreale HF, Franks S, Gambineri A, et al. The polycystic ovary syndrome: a position statement from the European Society of Endocrinology. *Eur J Endocrinol.* 2014;171(4):P1-29.
3. Fauser BC, Tarlatzis BC, Rebar RW, Legro RS, Balen AH, Lobo R, et al. Consensus on women's health aspects of polycystic ovary syndrome (PCOS): the Amsterdam ESHRE/ASRM-Sponsored 3rd PCOS Consensus Workshop Group. *Fertil Steril.* 2012;97(1):28-38 e25.
4. Kyrou I, Weickert MO, Randeve HS. Diagnosis and Management of Polycystic Ovary Syndrome (PCOS). In: Ajjan R, Orme SM, editors. *Endocrinology and Diabetes* Springer London; 2015. p. 99-113.
5. Randeve HS, Tan BK, Weickert MO, Lois K, Nestler JE, Sattar N, et al. Cardiometabolic aspects of the polycystic ovary syndrome. *Endocr Rev.* 2012;33(5):812-41.
6. Tahrani AA, Ali A, Stevens MJ. Obstructive sleep apnoea and diabetes: an update. *Curr Opin Pulm Med.* 2013;19(6):631-8.
7. Tahrani AA. Obstructive sleep apnea in patients with diabetes: implications for clinical practice. *Diabetes Management.* 2015;5(6):511-23.
8. Tahrani AA. Diabetes and sleep apnea. In: DeFronzo RA, Ferrannini E, Alberti G, editors. *International Textbook of Diabetes Mellitus.* 4th ed 2015. p. 316 - 36.
9. Engleman HM, Douglas NJ. Sleep. 4: Sleepiness, cognitive function, and quality of life in obstructive sleep apnoea/hypopnoea syndrome. *Thorax.* 2004;59(7):618-22.
10. Greenstone M, Hack M. Obstructive sleep apnoea. *BMJ.* 2014;348:g3745.
11. Lee W, Nagubadi S, Kryger MH, Mokhlesi B. Epidemiology of Obstructive Sleep Apnea: a Population-based Perspective. *Expert Rev Respir Med.* 2008;2(3):349-64.
12. Altaf QA, Barnett AH, Tahrani AA. Novel therapeutics for type 2 diabetes: insulin resistance. *Diabetes Obes Metab.* 2015;17(4):319-34.
13. Young T, Peppard PE, Gottlieb DJ. Epidemiology of obstructive sleep apnea: a population health perspective. *Am J Respir Crit Care Med.* 2002;165(9):1217-39.
14. Fogel RB, Malhotra A, Pillar G, Pittman SD, Dunaif A, White DP. Increased prevalence of obstructive sleep apnea syndrome in obese women with polycystic ovary syndrome. *J Clin Endocrinol Metab.* 2001;86(3):1175-80.
15. Vgontzas AN, Legro RS, Bixler EO, Grayev A, Kales A, Chrousos GP. Polycystic ovary syndrome is associated with obstructive sleep apnea and daytime sleepiness: role of insulin resistance. *J Clin Endocrinol Metab.* 2001;86(2):517-20.
16. Gopal M, Duntley S, Uhles M, Attarian H. The role of obesity in the increased prevalence of obstructive sleep apnea syndrome in patients with polycystic ovarian syndrome. *Sleep Med.* 2002;3(5):401-4.
17. Tasali E, Van Cauter E, Hoffman L, Ehrmann DA. Impact of obstructive sleep apnea on insulin resistance and glucose tolerance in women with polycystic ovary syndrome. *J Clin Endocrinol Metab.* 2008;93(10):3878-84.
18. Yang HP, Kang JH, Su HY, Tzeng CR, Liu WM, Huang SY. Apnea-hypopnea index in nonobese women with polycystic ovary syndrome. *Int J Gynaecol Obstet.* 2009;105(3):226-9.
19. de Sousa G, Schluter B, Buschatz D, Menke T, Trowitzsch E, Andler W, et al. A comparison of polysomnographic variables between obese adolescents with polycystic ovarian syndrome and healthy, normal-weight and obese adolescents. *Sleep Breath.* 2010;14(1):33-8.
20. Nandalike K, Agarwal C, Strauss T, Coupey SM, Isasi CR, Sin S, et al. Sleep and cardiometabolic function in obese adolescent girls with polycystic ovary syndrome. *Sleep Med.* 2012;13(10):1307-12.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

21. Tock L, Carneiro G, Togeiro SM, Hachul H, Pereira AZ, Tufik S, et al. Obstructive sleep apnea predisposes to nonalcoholic Fatty liver disease in patients with polycystic ovary syndrome. *Endocr Pract.* 2014;20(3):244-51.

22. Chatterjee B, Suri J, Suri JC, Mittal P, Adhikari T. Impact of sleep-disordered breathing on metabolic dysfunctions in patients with polycystic ovary syndrome. *Sleep Med.* 2014;15(12):1547-53.

23. Barber TM, McCarthy MI, Wass JA, Franks S. Obesity and polycystic ovary syndrome. *Clin Endocrinol (Oxf).* 2006;65(2):137-45.

24. Horejsi R, Moller R, Rackl S, Giuliani A, Freytag U, Crailsheim K, et al. Android subcutaneous adipose tissue topography in lean and obese women suffering from PCOS: comparison with type 2 diabetic women. *Am J Phys Anthropol.* 2004;124(3):275-81.

25. de Zegher F, Lopez-Bermejo A, Ibanez L. Adipose tissue expandability and the early origins of PCOS. *Trends Endocrinol Metab.* 2009;20(9):418-23.

26. Fogel RB, Malhotra A, White DP. Sleep. 2: pathophysiology of obstructive sleep apnoea/hypopnoea syndrome. *Thorax.* 2004;59(2):159-63.

27. Huang-Doran I, Franks S. Genetic Rodent Models of Obesity-Associated Ovarian Dysfunction and Subfertility: Insights into Polycystic Ovary Syndrome. *Front Endocrinol (Lausanne).* 2016;7:53.

28. Kapsimalis F, Kryger MH. Gender and obstructive sleep apnea syndrome, part 2: mechanisms. *Sleep.* 2002;25(5):499-506.

29. Lee EK, Gutcher ST, Douglass AB. Is sleep-disordered breathing associated with miscarriages? An emerging hypothesis. *Med Hypotheses.* 2014;82(4):481-5.

30. Baumgartner A, Dietzel M, Saletu B, Wolf R, Campos-Barros A, Graf KJ, et al. Influence of partial sleep deprivation on the secretion of thyrotropin, thyroid hormones, growth hormone, prolactin, luteinizing hormone, follicle stimulating hormone, and estradiol in healthy young women. *Psychiatry Res.* 1993;48(2):153-78.

31. Hall JE, Sullivan JP, Richardson GS. Brief wake episodes modulate sleep-inhibited luteinizing hormone secretion in the early follicular phase. *J Clin Endocrinol Metab.* 2005;90(4):2050-5.

32. Dunaif A, Segal KR, Futterweit W, Dobrjansky A. Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. *Diabetes.* 1989;38(9):1165-74.

33. Diamanti-Kandarakis E, Dunaif A. Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications. *Endocr Rev.* 2012;33(6):981-1030.

34. Franks S, Mason H, Willis D. Follicular dynamics in the polycystic ovary syndrome. *Mol Cell Endocrinol.* 2000;163(1-2):49-52.

35. Pamidi S, Wroblewski K, Broussard J, Day A, Hanlon EC, Abraham V, et al. Obstructive sleep apnea in young lean men: impact on insulin sensitivity and secretion. *Diabetes Care.* 2012;35(11):2384-9.

36. Lindberg E, Theorell-Haglow J, Svensson M, Gislason T, Berne C, Janson C. Sleep apnea and glucose metabolism: a long-term follow-up in a community-based sample. *Chest.* 2012;142(4):935-42.

37. Yang D, Liu Z, Yang H, Luo Q. Effects of continuous positive airway pressure on glycemic control and insulin resistance in patients with obstructive sleep apnea: a meta-analysis. *Sleep Breath.* 2013;17(1):33-8.

38. Iftikhar IH, Khan MF, Das A, Magalang UJ. Meta-analysis: continuous positive airway pressure improves insulin resistance in patients with sleep apnea without diabetes. *Ann Am Thorac Soc.* 2013;10(2):115-20.

39. Yang D, Liu Z, Yang H. The impact of effective continuous positive airway pressure on homeostasis model assessment insulin resistance in non-diabetic patients with moderate to severe obstructive sleep apnea. *Diabetes Metab Res Rev.* 2012;28(6):499-504.


40. Murri M, Luque-Ramirez M, Insenser M, Ojeda-Ojeda M, Escobar-Morreale HF. Circulating markers of oxidative stress and polycystic ovary syndrome (PCOS): a systematic review and meta-analysis. *Hum Reprod Update.* 2013;19(3):268-88.

- 421 41. Zuo T, Zhu M, Xu W. Roles of Oxidative Stress in Polycystic Ovary Syndrome and Cancers.  
422 *Oxid Med Cell Longev*. 2016;2016:8589318.
- 423 42. Chattopadhyay R, Ganesh A, Samanta J, Jana SK, Chakravarty BN, Chaudhury K. Effect of  
424 follicular fluid oxidative stress on meiotic spindle formation in infertile women with polycystic  
425 ovarian syndrome. *Gynecol Obstet Invest*. 2010;69(3):197-202.
- 426 43. Lavie L. Oxidative stress--a unifying paradigm in obstructive sleep apnea and comorbidities.  
427 *Prog Cardiovasc Dis*. 2009;51(4):303-12.
- 428 44. Sprung VS, Atkinson G, Cuthbertson DJ, Pugh CJ, Aziz N, Green DJ, et al. Endothelial function  
429 measured using flow-mediated dilation in polycystic ovary syndrome: a meta-analysis of the  
430 observational studies. *Clin Endocrinol (Oxf)*. 2013;78(3):438-46.
- 431 45. Pertynska-Marczewska M, Diamanti-Kandarakis E, Zhang J, Merhi Z. Advanced glycation end  
432 products: A link between metabolic and endothelial dysfunction in polycystic ovary syndrome?  
433 *Metabolism*. 2015;64(11):1564-73.
- 434 46. Tahrani AA, Ali A, Raymond NT, Begum S, Dubb K, Mughal S, et al. Obstructive sleep apnea  
435 and diabetic neuropathy: a novel association in patients with type 2 diabetes. *Am J Respir Crit Care*  
436 *Med*. 2012;186(5):434-41.
- 437 47. Jelic S, Lederer DJ, Adams T, Padeletti M, Colombo PC, Factor PH, et al. Vascular  
438 inflammation in obesity and sleep apnea. *Circulation*. 2010;121(8):1014-21.
- 439 48. Arnardottir ES, Mackiewicz M, Gislason T, Teff KL, Pack AI. Molecular signatures of  
440 obstructive sleep apnea in adults: a review and perspective. *Sleep*. 2009;32(4):447-70.
- 441 49. Schwarz EI, Puhan MA, Schlatzer C, Stradling JR, Kohler M. Effect of CPAP therapy on  
442 endothelial function in obstructive sleep apnoea: A systematic review and meta-analysis.  
443 *Respirology*. 2015;20(6):889-95.
- 444 50. Alvarez GE, Beske SD, Ballard TP, Davy KP. Sympathetic neural activation in visceral obesity.  
445 *Circulation*. 2002;106(20):2533-6.
- 446 51. Bell BB, Rahmouni K. Leptin as a Mediator of Obesity-Induced Hypertension. *Curr Obes Rep*.  
447 2016;5(4):397-404.
- 448 52. Lansdown A, Rees DA. The sympathetic nervous system in polycystic ovary syndrome: a  
449 novel therapeutic target? *Clin Endocrinol (Oxf)*. 2012;77(6):791-801.
- 450 53. Sverrisdottir YB, Mogren T, Kataoka J, Janson PO, Stener-Victorin E. Is polycystic ovary  
451 syndrome associated with high sympathetic nerve activity and size at birth? *Am J Physiol Endocrinol*  
452 *Metab*. 2008;294(3):E576-81.
- 453 54. Grassi G, Facchini A, Trevano FQ, Dell'Oro R, Arenare F, Tana F, et al. Obstructive sleep  
454 apnea-dependent and -independent adrenergic activation in obesity. *Hypertension*. 2005;46(2):321-  
455 5.
- 456 55. Xie A, Skatrud JB, Puleo DS, Morgan BJ. Exposure to hypoxia produces long-lasting  
457 sympathetic activation in humans. *J Appl Physiol* (1985). 2001;91(4):1555-62.
- 458 56. Loreda JS, Ziegler MG, Ancoli-Israel S, Clausen JL, Dimsdale JE. Relationship of arousals from  
459 sleep to sympathetic nervous system activity and BP in obstructive sleep apnea. *Chest*.  
460 1999;116(3):655-9.
- 461 57. Hedner J, Darpo B, Ejnell H, Carlson J, Caidahl K. Reduction in sympathetic activity after long-  
462 term CPAP treatment in sleep apnoea: cardiovascular implications. *Eur Respir J*. 1995;8(2):222-9.
- 463 58. Tasali E, Chapotot F, Leproult R, Whitmore H, Ehrmann DA. Treatment of obstructive sleep  
464 apnea improves cardiometabolic function in young obese women with polycystic ovary syndrome. *J*  
465 *Clin Endocrinol Metab*. 2011;96(2):365-74.

466

Study	Notes	n	OSA		Women with PCOS and OSA compared to women with PCOS without OSA							
			Diagnosis	%	Weight or BMI	WC or WHR	IR	Hyperandrogenism	BP	FPG	IGT	MS
Vgontzas et al. 2001; (15)	USA	53	AHI ≥10 + symptoms	11–17%	↑	NA	Insulin ↑*	FT and TT ↔	NA	↔	NA	NA
Fogel et al. 2001; (14)	USA	18	AHI >10	66.8%	NA	↑	NA	NA	NA	NA	NA	NA
Gopal et al. 2002; (16)	USA	23	RDI ≥5 + symptoms	69.6%	↔	NA	NA	NA	NA	NA	NA	NA
Tasali et al. 2008; (17)	USA	52	AHI ≥5	55.8%	↑	NA	HOMA-IR ↑*	FT and TT ↔	NA	↔	↑	NA
Yang et al. 2009; (18)	Taiwan, lean women	18	AHI ≥ 5	0%								
De Sousa et al. 2010; (19)	Germany, adolescents	22	Not stated	0%								
Nandalike et al. 2012; (20)	USA, adolescents, retrospective	28	AHI >5 or apnoea index >1	57.2%	↔	NA	HOMA-IR ↑	FT and TT ↔	↑	↔	NA	↑
Tock et al. 2014; (21)	Brazil	38	AHI ≥5	31.6%	↑	↑	HOMA-IR ↑	FT ↑*	NA	↔	↑	NA
Chatterjee et al. 2014; (22)	India	50	RDI ≥5 + symptoms or RDI >15	66%	↑	↑	HOMA-IR ↔	FT ↔	↑	↑*	NA	↑

**Table 1 Differences between women with PCOS and OSA compared to women with PCOS only.** n, number of participants; OSA, obstructive sleep apnoea; PCOS, polycystic ovary syndrome; AHI, apnoea/hypopnea index; RDI, respiratory distress index; BMI, body mass index; WC, waist circumference; WHR, waist-to-hip-ratio; IR, insulin resistance; HOMA-IR, homeostatic model assessment of insulin resistance; FT, Free testosterone; TT, total testosterone; BP, blood pressure; FPG, fasting plasma glucose; IGT, impaired glucose tolerance; MS, metabolic syndrome; ↑ statistically significant increase; NA, not available; ↔ equal; \*adjusted for weight.



**Figure 1. Possible mechanisms linking common shared features between Obstructive Sleep Apnoea (OSA) and Polycystic Ovary Syndrome (PCOS) with their clinical consequences.**